New insights in insurmountable antagonism

Fundamental and Clinical Pharmacology

Volumn 16, Issue 4, 2002, Pages 263-272

  Vauquelin, G ^a   Van Liefde, I ^a   Birzbier, B B ^a   Vanderheyden, P M L ^a  

^a VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

Author keywords

Antagonism; Cell lines; Insurmountable surmountable; Models; Noncompetitive competitive; Receptor

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANTIHISTAMINIC AGENT; CALCIUM CHANNEL BLOCKING AGENT; METHYSERGIDE; PROTON PUMP INHIBITOR; RECEPTOR BLOCKING AGENT; SEROTONIN 1 ANTAGONIST;

COMPETITIVE INHIBITION; COMPUTER SIMULATION; DOSE RESPONSE; DRUG ANTAGONISM; DRUG BINDING SITE; DRUG RECEPTOR BINDING; EXPERIMENTAL DESIGN; NONHUMAN; PRIORITY JOURNAL; PROTEIN CONFORMATION; REVIEW; SPECIES; TISSUE;

ALLOSTERIC REGULATION; BINDING, COMPETITIVE; COMPUTER SIMULATION; HUMANS; MODELS, BIOLOGICAL; RECEPTORS, CELL SURFACE;

EID: 0036403125     PISSN: 07673981     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1472-8206.2002.00095.x     Document Type: Review

References (95)

1. Gaddum J.H., Hameed K.A., Hathaway D.E., Stephens F.F. Quantitative studies of antagonists for 5-hydroxytryptamine. Quart. J. Exp. Physiol. (1955) 40 49-74.
2. Ariens E.J., Van Rossum J.M., Simmonis A.M. A theoretical basis of molecular pharmacology. Arzneim. Forsch. (1956) 6 611-621.
3. Ljung B. Vascular selectivity of felodipine. Drugs (1985) 29 46-58.
4. Coruzzi G., Adami M., Moretti U., Bertaccini G.T.I. Effect of omeprazole on gastric acid secretion by the rat isolated stomach. Pharmacol. Res. Commun. (1986) 18 257-271.
5. Tucek S., Proska J. Allosteric modulation of muscarinic acetylcholine receptors. Trends Pharmacol. Sci. (1995) 16 205-212.
6. Christopoulos A., Lanzafame A., Mitchelson F. Allosteric interactions at muscarinic cholinoceptors. Clin. Exp. Pharmacol. Physiol. (1998) 25 185-194.
7. Rang H.P. The kinetics of action of acetylcholine antagonists in smooth muscle. Proc. R. Soc. Lond. B Biol. Sci. (1966) 164 488-510.
8. Furchgott R.F. The use of b-haloalkylamines in the differentiation of receptors and in the determination of dissociation constants of receptor-agonist complexes. Adv. Drug Res. (1966) 3 21-55.
9. Paton W.D.M., Rang H.P. A kinetic approach to the mechanism of drug action. Adv. Drug Res. (1966) 3 57-80.
10. Paton W.D.M., Waud D.R. The margin of safety of neuromuscular transmission. J. Physiol. (1967) 191 59-90.
11. Bond R.A., Ornstein A.G., Clarke D.E. Unsurmountable antagonism to 5-hydroxytryptamine in rat kidney results from pseudoirreversible inhibition rather than multiple receptors or allosteric receptor modulation. J. Pharmacol. Exp. Ther. (1989) 249 401-410.
12. 2 receptor antagonists but allosteric modulators. Naunyn Schmiedebergs Arch. Pharmacol. (1987) 335 359-366.
13. Wong P.C., Timmermans P.B. Nonpeptide angiotensin II receptor antagonists. Insurmountable angiotensin II antagonism of EXP3892 is reversed by the surmountable antagonist DuP 753. J. Pharmacol. Exp. Ther. (1991) 258 49-57.
14. 1 receptors and their non-peptide antagonists. Biochem. Pharmacol. (2001) 61 277-284.
15. 2 receptor blockade by SR 48968 and MEN 10,627 in the guinea-pig isolated gallbladder and colon. Eur. J. Pharmacol. (1994) 271 111-119.
16. Williams T.J., Clarke D.E. Characterization of alpha 1-adrenoceptors mediating vasoconstriction to noradrenaline and nerve stimulation in the isolated perfused mesentery of rat. Br. J. Pharmacol. (1995) 114 531-536.
17. 2 receptor antagonists: no evidence for a correlation between lipophilicity and receptor affinity. Br. J. Pharmacol. (1996) 118 1813-1821.
18. Asghar A.U., Wheeldon A., Coleman R.A., Bountra C., McQueen D.S. Hoe 140 and pseudo-irreversible antagonism in the rat vas deferens in vitro. Eur. J. Pharmacol. (2000) 398 131-138.
19. 1 receptor subtype. Br. J. Pharmacol. (1993) 110 761-771.
20. 1 receptor antagonists: the role of tight antagonist binding. Eur. J. Pharmacol. (1999) 372 199-206.
21. 2-receptors. Naunyn Schmiedebergs Arch. Pharmacol. (1985) 328 295-300.
22. 2 receptors in tracheal smooth muscle. Naunyn Schmiedebergs Arch. Pharmacol. (1986) 333 91-97.
23. Kaumann A.J., Frenken M. ICI 169,369 is both a competitive antagonist and an allosteric activator of the arterial 5-hydroxytryptamine2 receptor system. J. Pharmacol. Exp. Ther. (1988) 245 1010-1015.
24. Frenken M., Kaumann A.J. Dimethylation of the activator ICI 169,369 results in a high-affinity partial deactivator, ICI 170,809, of the arterial 5-hydroxytryptamine-2 receptor system. J. Pharmacol. Exp. Ther. (1989) 250 707-713.
25. 2 receptor: a receptor, transducer coupling model to explain insurmountable antagonist effects. Drug Dev. Res. (1986) 8 173-178.
26. 1 receptor antagonism: the need for different antagonist binding states of the receptor. Trends Pharmacol. Res. (2001) 22 343-344.
27. Robertson M.J., Dougall I.G., Harper D., Mckechnie K.C.W., Leff P. Agonist-antagonist interactions at angiotensin receptors: application of a two-state receptor model. Trends Pharmacol. Sci. (1994) 15 364-369.
28. Liu Y.J., Shankley N.P., Welsh N.J., Black J.W. Evidence that the apparent complexity of receptor antagonism by angiotensin II analogues is due to a reversible, synoptic action. Br. J. Pharmacol. (1992) 106 233-241.
29. Ross E.M., Maguire M.E., Sturgill T.W., Biltonen R.L., Gilman A.G. Relationship between the beta-adrenergic receptor and adenylate cyclase. J. Biol. Chem. (1977) 252 5761-5775.
30. Lucas M., Homburger V., Dolphin A., Bockaert J. In vitro and in vivo kinetic analysis of the interaction of a norbornyl derivative of propranolol with beta-adrenergic receptors of brain and C6 glioma cells; an irreversible or slowly reversible ligand. Mol. Pharmacol. (1979) 15 588-597.
31. Clark R.B., Knoll B.J., Barber R. Partial agonists and G protein-coupled receptor desensitization. Trends Pharmacol. Sci. (1999) 20 279-286.
32. Onaran H.O., Gurdal H. Ligand efficacy and affinity in an interacting 7TM receptor model. Trends Pharmacol. Sci. (1999) 20 274-278.
33. Khorana H.G. Rhodopsin, photoreceptor of the rod cell. An emerging pattern for structure and function. J. Biol. Chem. (1992) 267 1-4.
34. Krumins A.M., Barber R. The stability of the agonist beta2-adrenergic receptor-Gs complex: evidence for agonist-specific states. Mol. Pharmacol. (1997) 52 144-154.
35. Thomas W.G., Qian H., Chang C.S., Karnik S. Agonist-induced phosphorylation of the angiotensin II (AT(1A)) receptor requires generation of a conformation that is distinct from the inositol phosphate-signaling state. J. Biol. Chem. (2000) 275 2893-2900.
36. 2 receptor antagonist. Eur. J. Pharmacol. (1993) 234 83-90.
37. Leff P., Martin G.R. The classification of 5-hydroxytryptamine receptors. Med. Res. Rev. (1988) 8 187-202.
38. 2 receptors. Proc. Natl Acad. Sci. USA (1993) 90 6194-6198.
39. Wienen W., Mauz A.B., Van Meel J.C., Entzeroth M. Different types of receptor interaction of peptide and nonpeptide angiotensin II antagonists revealed by receptor binding and functional studies. Mol. Pharmacol. (1992) 41 1081-1088.
40. Feniuk W. An analysis of 5-hydroxytryptamine receptors mediating contraction of isolated smooth muscle. Neuropharmacology (1984) 23 1467-1472.
41. Bradley P.B., Engel G., Feniuk W. et al. Proposals for the classification and nomenclature of functional receptors for 5-hydroxytryptamine. Neuropharmacology (1986) 25 563-576.
42. Xu Z., Purdy R.E. Evidence for allosteric blockade of serotonergic receptors in rabbit thoracic aorta. J. Pharmacol. Exp. Ther. (1989) 248 1091-1095.
43. 1D)-like receptor. Eur. J. Pharmacol. (2000) 408 69-82.
44. Forster C. Interaction of 5-methyl-urapidil with alpha 1-adrenoceptors in canine blood vessels: impact of pacing-induced heart failure. Eur. J. Pharmacol. (1996) 318 55-63.
45. Choppin A., Eglen R.M. Pharmacological characterization of muscarinic receptors in dog isolated ciliary and urinary bladder smooth muscle. Br. J. Pharmacol. (2001) 132 835-842.
46. 1 receptor antagonism: message in a model? Trends Pharmacol. Sci. (2001) 22 555-557.
47. Patacchini R., Giuliani S., Turini A., Navarra G., Maggi C.A. (2000) Effect of nepadutant at tachykinin NK(2) receptors in human intestine and urinary bladder. Eur. J. Pharmacol. (2001) 398 389-397.
48. Adams J.U., Paronis C.A., Holtzman S.G. Assessment of relative intrinsic activity of mu-opioid analgesics in vivo by using beta-funaltrexamine. J. Pharmacol. Exp. Ther. (1990) 255 1027-1032.
49. Walker E.A., Zernig G., Young A.M. In vivo apparent affinity and efficacy estimates for mu opiates in a rat tail-withdrawal assay. Psychopharmacology (1998) 136 15-23.
50. Miller T.R., Witte D.G., Ireland L.M. et al. Analysis of apparent noncompetitive responses to competitive H(1)-histamine receptor antagonists in fluorescent imaging plate reader-based calcium assays. J. Biomol. Screen (1999) 4 249-258.
51. 2+ mobilization by muscarinic antagonists. Biochem. Biophys. Res. Commun. (1998) 243 41-46.
52. 1 receptor antagonists. Trends Pharmacol. Sci. (2000) 21 376-381.
53. Pediani J.D., MacKenzie J.F., Heeley R.P., Daly C.J., McGrath J.C. Single-cell recombinant pharmacology: bovine alpha(1a)-adrenoceptors in rat-1 fibroblasts release intracellular Ca(2+), display subtype-characteristic agonism and antagonism, and exhibit an antagonist-reversible inverse concentration-response phase. J. Pharmacol. Exp. Ther. (2000) 293 887-895.
54. Christopoulos A., Parsons A.M., Lew M.J., El-Fakahany E.E. The assessment of antagonist potency under conditions of transient response kinetics. Eur. J. Pharmacol. (1999) 382 217-227.
55. 2-like receptors. Can they be classified with the available antagonists? Br. J. Pharmacol. (1986) 88 585-593.
56. 1 receptors. Br. J. Pharmacol. (1999) 126 1057-1065.
57. 1 receptor-transfected Chinese hamster ovary cells Eur. J. Pharmacol. (1999) 367 413-422.
58. 1 receptor differently affects the binding of surmountable and insurmountable non-peptide antagonists. J. Renin Angiotensin Aldosterone Syst. (2000) 1 283-288.
59. Kushida H., Nomura S., Morita O. et al. Pharmacological characterization of the nonpeptide angiotensin II receptor antagonist, U-97018. J. Pharmacol. Exp. Ther. (1995) 274 1042-1053.
60. 1-receptor antagonist. J. Cardiovasc. Pharmacol. (1999) 34 526-532.
61. 3 receptor-mediated electrical response in cultured mouse neuroblastoma cells. Neuropharmacology (1988) 27 301-307.
62. 3 receptors. Neuropharmacology (1993) 32 729-735.
63. Dunlop J., Pass I., Ennis C. The cholecystokinin-B receptor antagonist L-740,093 produces an insurmountable antagonism of CCK-4 stimulated functional response in cells expressing the human CCK-B receptor. Neuropeptides (1998) 32 157-160.
64. Aramori I., Zenkoh J., Morikawa N. et al. Novel subtype-selective nonpeptide bradykinin receptor antagonists FR167344 and FR173657. Mol. Pharmacol. (1997) 51 171-176.
65. 1 receptor. J. Biol. Chem. (1995) 270 1493-1496.
66. Dickinson K.E., Cohen R.B., Skwish S. et al. BMS-180560, an insurmountable inhibitor of angiotensin II-stimulated responses: comparison with losartan and EXP3174. Br. J. Pharmacol. (1994) 113 179-189.
67. Christopoulos A. From 'captive' agonism to insurmountable antagonism: demonstrating the power of analytical pharmacology. Clin. Exp. Pharmacol. Physiol. (2001) 28 223-229.
68. el-Fakahany E.E., Surichamorn W., Amrhein C.L. et al. Pseudo-noncompetitive antagonism of muscarinic receptor-mediated cyclic GMP formation and phosphoinositide hydrolysis by pirenzepin. J. Pharmacol. Exp. Ther. (1988) 247 934-940.
69. Thomas E.A., Carson M.J., Neal M.J., Sutcliffe J.G. (1997) Unique allosteric regulation of 5-hydroxytryptamine receptor-mediated signal transduction by oleamide. Proc. Natl. Acad. Sci. USA (1988) 94 14115-14119.
70. Ortmann R., Perkins J.P. Stimulation of adenosine 3′:5′-monophosphate formation by prostaglandins in human astro-cytoma cells. Inhibition by nonsteroidal anti-inflammatory agents. J. Biol. Chem. (1977) 252 6018-6025.
71. 2 receptor. Pharmacology (1999) 59 1-10.
72. A endothelin receptor Biochem. Biophys. Res. Commun. (1994) 200 679-686.
73. Lachnit W.G., Oglesby I.B., Gever J.R. et al. Regulated expression of the rat recombinant P2X (3) receptor in stably transfected CHO-K1 tTA cells. J. Auton. Nerv. Syst. (2000) 81 75-81.
74. Houle S., Larrivée J.F., Bachvarova M., Bouthillier J., Bachvarov D.R., Marceau F. Antagonist-induced intracellular sequestration of rabbit bradykinin B(2) receptor. Hypertension (2000) 35 1319-1325.
75. McConnell H.M., Owicki J.R., Parce J.W. et al. The cytosensor microphysiometer: biological applications of silicon technology. Science (1992) 257 1906-1912.
76. Dunlop J., Brammer N., Evans N., Ennis C. (1997) YM022 [(R)-1-[2,3-dihydro-1-(2′-methylphenacyl)-2-oxo-5-phenyl-1H-1,4- benzodiazepin-3-yl]-3-(3-methylphenyl) urea]: an irreversible cholecystokinin type-B receptor antagonist. Biochem. Pharmacol. (1992) 54 81-85.
77. 2 receptors in imr-90 and int-407 human cell lines using a microphysiometer. Clin. Exp. Pharmacol. Physiol. (2001) 28 402-408.
78. 1 receptor antagonist, UR-7280. Eur. J. Pharmacol. (1996) 318 341-347.
79. A receptors. Eur. J. Pharmacol. (1993) 245 229-232.
80. Chin M.H., Cioffi C.L., Garay M. et al. The unusual binding properties of the endothelin receptor antagonist CGS 27830 distinguishes receptor/agonist interactions. J. Pharmacol. Exp. Ther. (1996) 276 74-83.
81. Hara M., Kiyama R., Nakajima S. et al. Kinetic studies on the interaction of nonlabeled antagonists with the angiotensin II receptor Eur. J. Pharmacol. (1995) 289 267-273.
82. Pendleton R.G., Gessner G., Horner E. Studies on inhibition of angiotensin II receptors in rabbit adrenal and aorta. J. Pharmacol. Exp. Ther. (1989) 248 637-643.
83. Tamura K., Okuhira M., Amano H. et al. Pharmacologic profiles of KRH-594, a novel nonpeptide angiotensin II-receptor antagonist. J. Cardiovasc. Pharmacol. (1997) 30 607-615.
84. Larrivee J.F., Gera L., Houle S. et al. Non-competitive pharmacological antagonism at the rabbit B(1) receptor. Br. J. Pharmacol. (2000) 131 885-892.
85. Lee N.H., el-Fakahany E.E. Allosteric antagonists of the muscarinic acetylcholine receptor. Biochem. Pharmacol. (1991) 42 199-205.
86. Kostenis E., Mohr K. Two-point kinetic experiments to quantify allosteric effects on radioligand dissociation. Trends Pharmacol. Sci. (1996) 17 280-283.
87. Christopoulos A., Pierce T.L., Sorman J.L., El-Fakahany E.E. On the unique binding and activating properties of xanomeline at the M1 muscarinic acetylcholine receptor. Mol. Pharmacol. (1998) 53 1120-1130.
88. Verheijen I., Fierens F.L.P., De Backer J.-P., Vauquelin G., Vanderheyden P.M.L. Interaction between the partially insurmountable antagonist valsartan and human recombinant angiotensin II type 1 receptors. Fund. Clin. Pharmacol. (2001) 14 577-585.
89. 1 antagonism. J. Pharmacol. Exp. Ther. (1995) 273 753-761.
90. 1 receptor. Eur. J. Pharmacol. (1997) 319 137-146.
91. Mendes P. Biochemistry by numbers: simulation of biochemical pathways with Gepasi 3. Trends Biochem. Sci. (1997) 22 361-363.
92. Timmermans P.B. Pharmacological properties of angiotensin II receptor antagonists. Can. J. Cardiol. (1999) 15 26F-28F.
93. Dollery C.J., Dargie H.J., Sassard J., Cuisinard G. Concentration effect relationship with FM24: a new long acting β-adrenergic receptor antagonist. Br. J. Clin. Pharmacol. (1983) 15 707-713.
94. Unger T. Significance of angiotensin type 1 receptor blockade: why are angiotensin II receptor blockers different? Am. J. Cardiol. (1999) 84 9S-15S.
95. Gero A. Desensitization, two-state receptors and pharmacological parameters. J. Theor. Biol. (1983) 103 137-161.